文献速递血管炎

血管内皮生长因子能否作为巨细胞动脉炎的有用生物标志物?

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
PubMed 文献 · RMD Open · 2017-03-29

基于TABUL多中心研究队列的298例疑似巨细胞动脉炎(GCA)患者,在26例活检确诊GCA与26例对照的随机子集中分析血清VEGF浓度。第0周GCA组平均VEGF为873 pg/mL,对照组为476 pg/mL(p=0.017),713 pg/mL cut-off在全队列的灵敏度为32%、特异度85%,联合临床参数未改善;在活检确诊GCA中灵敏度58%、特异度85%。结论:血清VEGF预测活检阳性,但不能区分临床GCA病例与对照。

要点

  • 第0周血清VEGF在活检确诊GCA组高于对照(873 vs 476 pg/mL,p=0.017)。
  • 713 pg/mL cut-off在全队列灵敏度32%、特异度85%,联合临床参数未改善。
  • 活检确诊GCA中灵敏度58%、特异度85%,VEGF预测活检阳性但不足以区分临床病例。

核心结论

  • 血清VEGF浓度可预测颞动脉活检阳性,但不足以区分临床疑诊GCA患者与对照。

研究设计与样本

  • 从TABUL多中心研究纳入298例疑似GCA患者,在26例活检确诊GCA与26例对照的随机子集中用ELISA检测第0、2、26周血清VEGF。
  • 第0周VEGF用于生成ROC曲线确定异常cut-off,并应用于全队列298例。
  • 对石蜡包埋颞动脉切片行VEGF免疫组化染色。

主要发现

  • 第0周平均(95%CI)VEGF在26例GCA为873 pg/mL(631至1110),26例对照为476 pg/mL(328至625),p=0.017。
  • 该差异在其他时间点未观察到。
  • 活检阳性GCA的颞动脉切片外膜见强烈染色,对照未见。

关键数值与推荐

  • 第0周VEGF最佳cut-off为713 pg/mL,全队列(n=298)灵敏度32%、特异度85%。
  • 联合任何临床参数均未改善该cut-off的诊断性能。
  • 活检确诊GCA与对照比较时,灵敏度58%、特异度85%。

临床怎么用

  • 血清VEGF不宜单独用于区分临床疑诊GCA与对照。
  • VEGF升高可提示活检阳性可能,但灵敏度有限,不能替代活检。
  • VEGF作为预后标志物和治疗靶点值得进一步研究。

局限性

  • VEGF分析仅在26例活检确诊GCA与26例对照的随机子集中进行。
  • cut-off来自小样本子集,应用于全队列时灵敏度仅32%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the performance of circulating vascular endothelial growth factor (VEGF) levels as a tool for diagnosing giant cell arteritis (GCA) in a cohort of patients referred for assessment of suspected GCA. METHODS: We selected 298 patients recruited to the multicentre study Temporal Artery Biopsy versus Ultrasound in diagnosis of suspected GCA (TABUL). In a random subset of 26 biopsy-proven GCA cases and 26 controls, serum from weeks 0, 2 and 26 was analysed for VEGF concentration using ELISA. VEGF concentration at week 0 was used to generate a receiver-operating characteristic curve and thereby identify a cut-off for an abnormal result which was used to analyse the full patient cohort. Sections of paraffin-embedded temporal artery were stained by immunohistochemistry for VEGF. RESULTS: The mean (95% CI) VEGF concentration at week 0 was 873 pg/mL (631 to 1110) in 26 patients versus 476 pg/mL (328 to 625) in 26 controls (p=0.017). This difference was not observed at any other time point. The optimal cut-off of 713 pg/mL was applied to the whole patient cohort (n=298), yielding sensitivity of 32% and specificity of 85%. This was not improved by combination with any clinical parameters. When patients with biopsy-proven GCA were compared with controls, sensitivity was 58% and specificity remained 85%. Sections of biopsy from biopsy-positive GCA showed intense staining in the adventitia which was not seen in controls. CONCLUSIONS: Serum VEGF concentration predicts biopsy positivity but is not useful for differentiating clinical cases of GCA from controls. Further studies into VEGF as a prognostic marker and therapeutic target are warranted. TRIAL REGISTRATION NUMBER: NCT00974883; Post-results.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Goodfellow N, Morlet J, Singh S, et al. Is vascular endothelial growth factor a useful biomarker in giant cell arteritis? RMD Open. 2017. PMID: 28405470. doi:10.1136/rmdopen-2016-000353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。